




Teduglutide

Revised: September 15, 2023.

CASRN: 197922-42-2



Drug Levels and Effects

Summary of Use during Lactation

Because it is a large protein molecule with a molecular weight of 3752 Da, the amount in milk is likely to be very low. Teduglutide is also poorly absorbed orally so absorption by a breastfed infant is unlikely. Two breastfed infants apparently experienced no adverse effects during maternal use of teduglutide, but no long-term data are available. Until more data are available, teduglutide should be used with careful infant monitoring during breastfeeding.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

One mother used teduglutide during pregnancy and postpartum while breastfeeding. She breastfed her infant (extent not stated) for 6 months. No mention was made of any adverse effects in the infant.[1]

A woman taking teduglutide because of removal of a portion of her gastrointestinal tract became pregnant and delivered a healthy infant. She breastfed her infant and the drug was restarted 1 month after delivery. She breastfed (extent not stated) her infant for another 4 months during treatment. The infant experienced no side effects during breastfeeding.[2]

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1. Gentilini MV, Doeyo M, Ortega M, et al. Successful pregnancy in a patient with short bowel syndrome after surgical rehabilitation and sGLP-2 treatment: Novel report on endogenous GLP-2 levels at delivery and during breastfeeding. *Therap Adv Gastroenterol* 2022;15:17562848221129787.
2. Lillienau J, Nilsson E, Vulcan A, Nilsson A. 90: Use of teduglutide during breast-feeding after pregnancy in a patient with severe intestinal failure. *Transplantation* 2023;107:53. doi:10.1097/01.tp.0000945816.46782.83 PubMed PMID: 36508646.

Substance Identification

Substance Name

Teduglutide

CAS Registry Number

197922-42-2

Drug Class

Breast Feeding

Lactation

Milk, Human

Incretins

Glucagon-Like Peptide-1 Agonists

GLP-1 Agonists